• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

内科病房中的急性细菌性皮肤和皮肤结构感染:新旧药物

Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs.

作者信息

Falcone Marco, Concia Ercole, Giusti Massimo, Mazzone Antonino, Santini Claudio, Stefani Stefania, Violi Francesco

机构信息

Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Policlinico Umberto I, Viale Dell'Università 37, 00161, Rome, Italy.

Department of Pathology, University of Verona, Verona, Italy.

出版信息

Intern Emerg Med. 2016 Aug;11(5):637-48. doi: 10.1007/s11739-016-1450-6. Epub 2016 Apr 15.

DOI:10.1007/s11739-016-1450-6
PMID:27084183
Abstract

Skin and soft tissue infections (SSTIs) are a common cause of hospital admission among elderly patients, and traditionally have been divided into complicated and uncomplicated SSTIs. In 2010, the FDA provided a new classification of these infections, and a new category of disease, named acute bacterial skin and skin structure infections (ABSSSIs), has been proposed as an independent clinical entity. ABSSSIs include three entities: cellulitis and erysipelas, wound infections, and major cutaneous abscesses This paper revises the epidemiology of SSTIs and ABSSSIs with regard to etiologies, diagnostic techniques, and clinical presentation in the hospital settings. Particular attention is owed to frail patients with multiple comorbidities and underlying significant disease states, hospitalized on internal medicine wards or residing in nursing homes, who appear to be at increased risk of infection due to multi-drug resistant pathogens and treatment failures. Management of ABSSSIs and SSTIs, including evaluation of the hemodynamic state, surgical intervention and treatment with appropriate antibiotic therapy are extensively discussed.

摘要

皮肤及软组织感染(SSTIs)是老年患者住院的常见原因,传统上分为复杂性和非复杂性SSTIs。2010年,美国食品药品监督管理局(FDA)对这些感染进行了新的分类,并提出了一种名为急性细菌性皮肤和皮肤结构感染(ABSSSIs)的新疾病类别作为一个独立的临床实体。ABSSSIs包括三种情况:蜂窝织炎和丹毒、伤口感染以及主要的皮肤脓肿。本文就医院环境中SSTIs和ABSSSIs在病因、诊断技术和临床表现方面的流行病学进行了修订。尤其要关注患有多种合并症和潜在重大疾病的体弱患者,这些患者在内科病房住院或住在养老院,由于多重耐药病原体和治疗失败,他们似乎感染风险增加。本文还广泛讨论了ABSSSIs和SSTIs的管理,包括血流动力学状态评估、手术干预和适当的抗生素治疗。

相似文献

1
Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs.内科病房中的急性细菌性皮肤和皮肤结构感染:新旧药物
Intern Emerg Med. 2016 Aug;11(5):637-48. doi: 10.1007/s11739-016-1450-6. Epub 2016 Apr 15.
2
[Therapy of SSTI and role of tigecycline].[皮肤和软组织感染的治疗及替加环素的作用]
Infez Med. 2009 Sep;17 Suppl 4:64-76.
3
Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections.耐甲氧西林金黄色葡萄球菌感染的患病率及治疗进展
Expert Rev Anti Infect Ther. 2007 Dec;5(6):961-81. doi: 10.1586/14787210.5.6.961.
4
Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment.皮肤和软组织感染:批判性评价及替考拉宁在其治疗中的作用。
Clin Infect Dis. 2015 Sep 15;61 Suppl 2:S69-78. doi: 10.1093/cid/civ528.
5
Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections.与糖肽类药物对比的随机临床试验支持将达托霉素用作复杂性皮肤和软组织感染的一线治疗药物。
Int J Antimicrob Agents. 2012 Jan;39(1):90-1. doi: 10.1016/j.ijantimicag.2011.08.007. Epub 2011 Oct 5.
6
Antimicrobial agents in treatment of MRSA infections.用于治疗耐甲氧西林金黄色葡萄球菌(MRSA)感染的抗菌药物。
Dis Mon. 2008 Dec;54(12):793-800. doi: 10.1016/j.disamonth.2008.09.002.
7
In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.2011-2014 年欧洲和北美的临床感染分离的葡萄球菌、链球菌和肠球菌对奥利万星及其他比较药物的体外活性研究。
Int J Antimicrob Agents. 2015 Dec;46(6):674-81. doi: 10.1016/j.ijantimicag.2015.08.014. Epub 2015 Oct 20.
8
[Skin and soft tissue infections: current therapeutic options].
Infez Med. 2008 Jun;16(2):65-73.
9
Retrospective case-control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy.回顾性病例对照分析接受达托霉素或糖肽类药物治疗的葡萄球菌感染患者。
Int J Antimicrob Agents. 2012 Jan;39(1):64-8. doi: 10.1016/j.ijantimicag.2011.09.011. Epub 2011 Nov 1.
10
New antibiotics in the management of acute bacterial skin and skin structure infections.新型抗生素在急性细菌性皮肤及皮肤结构感染治疗中的应用
Skin Therapy Lett. 2015 Sep-Oct;20(5):7-9.

引用本文的文献

1
Novel Triazeneindole Antibiotics: Synthesis and Hit-to-Lead Optimization.新型三氮烯吲哚抗生素:合成与从苗头化合物到先导化合物的优化
Int J Mol Sci. 2025 Feb 21;26(5):1870. doi: 10.3390/ijms26051870.
2
The future approach for the management of acute bacterial skin and skin structure infections.急性细菌性皮肤和皮肤结构感染的未来管理方法。
Curr Opin Infect Dis. 2025 Apr 1;38(2):128-135. doi: 10.1097/QCO.0000000000001092. Epub 2025 Jan 15.
3
Efficacy and safety of omadacycline for treating complicated skin and soft tissue infections: a meta-analysis of randomized controlled trials.

本文引用的文献

1
A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.单剂量与每周一次达巴万星治疗急性细菌性皮肤和皮肤结构感染的随机临床试验
Clin Infect Dis. 2016 Mar 1;62(5):545-51. doi: 10.1093/cid/civ982. Epub 2015 Nov 26.
2
Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment.皮肤和软组织感染:批判性评价及替考拉宁在其治疗中的作用。
Clin Infect Dis. 2015 Sep 15;61 Suppl 2:S69-78. doi: 10.1093/cid/civ528.
3
Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005-2010.
奥马环素治疗复杂性皮肤和软组织感染的疗效和安全性:一项随机对照试验的荟萃分析。
BMC Infect Dis. 2024 Feb 19;24(1):219. doi: 10.1186/s12879-024-09097-3.
4
Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals.在两家意大利医院中,达巴万星与标准治疗方案治疗急性细菌性皮肤和皮肤结构感染(ABSSSIs)的成本分析。
JAC Antimicrob Resist. 2023 Apr 19;5(2):dlad044. doi: 10.1093/jacamr/dlad044. eCollection 2023 Apr.
5
Daptomycin Population Pharmacokinetics in Patients Affected by Severe Gram-Positive Infections: An Update.严重革兰氏阳性感染患者中达托霉素群体药代动力学:最新进展
Antibiotics (Basel). 2022 Jul 7;11(7):914. doi: 10.3390/antibiotics11070914.
6
Real-World Evidence of Efficacy and Safety of Levonadifloxacin (Oral and IV) in the Management of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Findings of a Retrospective, Multi-Center Study.左氧氟沙星(口服和静脉注射)治疗急性细菌性皮肤及皮肤结构感染(ABSSSI)的疗效和安全性的真实世界证据:一项回顾性多中心研究的结果
Cureus. 2022 Apr 20;14(4):e24299. doi: 10.7759/cureus.24299. eCollection 2022 Apr.
7
Lipid Nanoparticulate Drug Delivery Systems: Recent Advances in the Treatment of Skin Disorders.脂质纳米颗粒药物递送系统:皮肤疾病治疗的最新进展
Pharmaceuticals (Basel). 2021 Oct 26;14(11):1083. doi: 10.3390/ph14111083.
8
What COVID-19 taught us: New opportunities and pathways from telemedicine and novel antiseptics in wound healing.新冠疫情教会了我们什么:远程医疗和新型伤口愈合抗菌剂带来的新机遇和新途径。
Int Wound J. 2022 Aug;19(5):987-995. doi: 10.1111/iwj.13695. Epub 2021 Oct 2.
9
Determination of Delafloxacin in Pharmaceutical Formulations Using a Green RP-HPTLC and NP-HPTLC Methods: A Comparative Study.采用绿色反相高效薄层色谱法和正相高效薄层色谱法测定药物制剂中的德拉氟沙星:一项对比研究
Antibiotics (Basel). 2020 Jun 25;9(6):359. doi: 10.3390/antibiotics9060359.
10
Anti-Inflammatory Activity of Miodesin™: Modulation of Inflammatory Markers and Epigenetic Evidence.Miodesin™ 的抗炎活性:炎症标志物的调节和表观遗传学证据。
Oxid Med Cell Longev. 2020 May 15;2020:6874260. doi: 10.1155/2020/6874260. eCollection 2020.
2005 - 2010年门诊和住院患者中皮肤及软组织感染的发病率
BMC Infect Dis. 2015 Aug 21;15:362. doi: 10.1186/s12879-015-1071-0.
4
Treatment outcome measures for randomized controlled trials of antibiotic treatment for acute bacterial skin and skin structure infections in the emergency department setting.急诊科环境下急性细菌性皮肤和皮肤结构感染抗生素治疗随机对照试验的治疗结局指标。
Int J Emerg Med. 2015 Apr 22;8:11. doi: 10.1186/s12245-015-0060-9. eCollection 2015.
5
Early response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections: analysis of the REACH study.欧洲复杂皮肤及软组织感染住院患者对抗生素治疗的早期反应:REACH研究分析
BMC Infect Dis. 2015 Feb 19;15:78. doi: 10.1186/s12879-015-0822-2.
6
How to choose the duration of antibiotic therapy in patients with pneumonia.如何选择肺炎患者的抗生素治疗疗程。
Curr Opin Infect Dis. 2015 Apr;28(2):177-84. doi: 10.1097/QCO.0000000000000140.
7
Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.单剂奥塔万古霉素与 7-10 天万古霉素治疗革兰阳性急性细菌性皮肤和皮肤结构感染:SOLO II 非劣效性研究。
Clin Infect Dis. 2015 Jan 15;60(2):254-62. doi: 10.1093/cid/ciu778. Epub 2014 Oct 6.
8
Resource use in patients hospitalized with complicated skin and soft tissue infections in Europe and analysis of vulnerable groups: the REACH study.欧洲复杂皮肤和软组织感染住院患者的资源利用及弱势群体分析:REACH研究
J Med Econ. 2014 Oct;17(10):719-29. doi: 10.3111/13696998.2014.940423. Epub 2014 Jul 25.
9
Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.皮肤和软组织感染诊断与管理实践指南:美国传染病学会 2014 年更新版。
Clin Infect Dis. 2014 Jul 15;59(2):e10-52. doi: 10.1093/cid/ciu444.
10
Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria.欧洲耐甲氧西林金黄色葡萄球菌所致复杂性皮肤软组织感染患者的抗生素治疗模式:呼吁实施早期转换和早期出院标准。
Int J Antimicrob Agents. 2014 Jul;44(1):56-64. doi: 10.1016/j.ijantimicag.2014.04.007. Epub 2014 May 16.